Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive brain cancer: dual immunotherapy trial launches

NCT ID NCT05734560

Recruiting now Disease control Sponsor: Darell Bigner Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 25 times

Summary

This study tests a combination of two experimental drugs, D2C7-IT and 2141-V11, for adults with a fast-growing brain tumor called glioblastoma that has not responded to standard chemotherapy. The drugs are given directly into the brain after surgery, followed by under-the-skin injections near the lymph nodes. The goal is to see if this approach is safe and helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA